Non-ocular Tumors

Brian Tse, Rachel C. Brennan, Carlos Rodriguez-Galindo, Matthew W. Wilson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the management of retinoblastoma, it is important to remember that there is an entire patient to treat – not just an intraocular tumor. Children with heritable retinoblastoma who have a germ-line mutation in RB1 have an increased risk of developing a second malignancy. All familial cases, all bilateral cases, and approximately 15 % of unilateral cases fall into this category. The most common secondary malignancies are sarcomas, melanoma, and brain tumors. The association of retinoblastoma and an intracranial neuroblastic malignancy, known as “trilateral retinoblastoma,” most often involves the pineal gland (“pineoblastoma/pinealoblastoma”) but may also involve parasellar and suprasellar regions ( Chap. 20 [1–3]. The increased risk of developing second, non-ocular malignancies for survivors of heritable retinoblastoma is estimated to be 20 times higher than the general population [4].

Original languageEnglish (US)
Title of host publicationClinical Ophthalmic Oncology: Retinoblastoma, Second Edition
PublisherSpringer Berlin Heidelberg
Pages201-208
Number of pages8
ISBN (Print)9783662434512, 9783662434505
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Retinoblastoma
Neoplasms
Pinealoma
Pineal Gland
Second Primary Neoplasms
Germ-Line Mutation
Brain Neoplasms
Sarcoma
Survivors
Melanoma
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tse, B., Brennan, R. C., Rodriguez-Galindo, C., & Wilson, M. W. (2015). Non-ocular Tumors. In Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition (pp. 201-208). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-43451-2_19

Non-ocular Tumors. / Tse, Brian; Brennan, Rachel C.; Rodriguez-Galindo, Carlos; Wilson, Matthew W.

Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg, 2015. p. 201-208.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tse, B, Brennan, RC, Rodriguez-Galindo, C & Wilson, MW 2015, Non-ocular Tumors. in Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg, pp. 201-208. https://doi.org/10.1007/978-3-662-43451-2_19
Tse B, Brennan RC, Rodriguez-Galindo C, Wilson MW. Non-ocular Tumors. In Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg. 2015. p. 201-208 https://doi.org/10.1007/978-3-662-43451-2_19
Tse, Brian ; Brennan, Rachel C. ; Rodriguez-Galindo, Carlos ; Wilson, Matthew W. / Non-ocular Tumors. Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg, 2015. pp. 201-208
@inbook{370110e8c9584d6c901db0b1f4bf0a39,
title = "Non-ocular Tumors",
abstract = "In the management of retinoblastoma, it is important to remember that there is an entire patient to treat – not just an intraocular tumor. Children with heritable retinoblastoma who have a germ-line mutation in RB1 have an increased risk of developing a second malignancy. All familial cases, all bilateral cases, and approximately 15 {\%} of unilateral cases fall into this category. The most common secondary malignancies are sarcomas, melanoma, and brain tumors. The association of retinoblastoma and an intracranial neuroblastic malignancy, known as “trilateral retinoblastoma,” most often involves the pineal gland (“pineoblastoma/pinealoblastoma”) but may also involve parasellar and suprasellar regions ( Chap. 20 [1–3]. The increased risk of developing second, non-ocular malignancies for survivors of heritable retinoblastoma is estimated to be 20 times higher than the general population [4].",
author = "Brian Tse and Brennan, {Rachel C.} and Carlos Rodriguez-Galindo and Wilson, {Matthew W.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-662-43451-2_19",
language = "English (US)",
isbn = "9783662434512",
pages = "201--208",
booktitle = "Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Non-ocular Tumors

AU - Tse, Brian

AU - Brennan, Rachel C.

AU - Rodriguez-Galindo, Carlos

AU - Wilson, Matthew W.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In the management of retinoblastoma, it is important to remember that there is an entire patient to treat – not just an intraocular tumor. Children with heritable retinoblastoma who have a germ-line mutation in RB1 have an increased risk of developing a second malignancy. All familial cases, all bilateral cases, and approximately 15 % of unilateral cases fall into this category. The most common secondary malignancies are sarcomas, melanoma, and brain tumors. The association of retinoblastoma and an intracranial neuroblastic malignancy, known as “trilateral retinoblastoma,” most often involves the pineal gland (“pineoblastoma/pinealoblastoma”) but may also involve parasellar and suprasellar regions ( Chap. 20 [1–3]. The increased risk of developing second, non-ocular malignancies for survivors of heritable retinoblastoma is estimated to be 20 times higher than the general population [4].

AB - In the management of retinoblastoma, it is important to remember that there is an entire patient to treat – not just an intraocular tumor. Children with heritable retinoblastoma who have a germ-line mutation in RB1 have an increased risk of developing a second malignancy. All familial cases, all bilateral cases, and approximately 15 % of unilateral cases fall into this category. The most common secondary malignancies are sarcomas, melanoma, and brain tumors. The association of retinoblastoma and an intracranial neuroblastic malignancy, known as “trilateral retinoblastoma,” most often involves the pineal gland (“pineoblastoma/pinealoblastoma”) but may also involve parasellar and suprasellar regions ( Chap. 20 [1–3]. The increased risk of developing second, non-ocular malignancies for survivors of heritable retinoblastoma is estimated to be 20 times higher than the general population [4].

UR - http://www.scopus.com/inward/record.url?scp=84956824418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956824418&partnerID=8YFLogxK

U2 - 10.1007/978-3-662-43451-2_19

DO - 10.1007/978-3-662-43451-2_19

M3 - Chapter

SN - 9783662434512

SN - 9783662434505

SP - 201

EP - 208

BT - Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition

PB - Springer Berlin Heidelberg

ER -